NanoMuG

Biotechnology Research • Via Nizza, 44, Italy • 1-10 Employees

Company overview

Headquarters	Via Nizza, 44, Turin, Piedmont 10125, IT
Phone number	+3902099550010
Website	nanomug.it
NAICS	541714
Employees	1-10

Key Contact at NanoMuG

Paola Petrini

Scientifc Advisor and Co-Founder of NanoMuG

About NanoMuG

At Nanomug we harness the power of nature’s defense mechanisms by developing a revolutionary drug delivery platform based on glycosylated mucin nanoparticles. This innovative technology redefines pharmaceutical development through API repurposing and by maximizing targeting and mucoadhesivity, ultimately delivering unmatched therapeutic solutions. Our platform seamlessly integrates synthesis, drug encapsulation, and functionalization into a single-step process, optimizing both targeting and mucoadhesivity for enhanced performance. Capable of encapsulating a diverse range of bioactive compounds—from small molecules to proteins—our mucosomes achieve high entrapment efficiency. Engineered with sustainability in mind, our technology utilizes mucin derived from food industry by-products, minimizes solvent use, reduces waste, and provides a scalable, cost-effective solution for pharmaceutical innovation. Our vision is to become the strategic partner of choice for the pharmaceutical market, offering versatile, high-impact solutions in infectious diseases, oncology, and other mucosal health applications. Through relentless innovation, we empower our partners to deliver breakthrough therapies that transform healthcare and improve patient outcomes.

NanoMuG revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	No funding